The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis

被引:38
|
作者
Luchavova, Maria [1 ,3 ]
Zikan, Vit [1 ,3 ]
Michalska, Dana [1 ,3 ]
Raska, Ivan, Jr. [1 ,3 ]
Kubena, Ales A. [2 ]
Stepan, Jan J. [4 ]
机构
[1] Gen Univ Hosp Prague, CZ-12808 Prague, Czech Republic
[2] Acad Sci Czech Republic, Inst Informat Theory & Automat, CZ-18208 Prague, Czech Republic
[3] Charles Univ Prague, Dept Internal Med 3, Dept Endocrinol & Metab, Fac Med 1, CZ-12808 Prague, Czech Republic
[4] Charles Univ Prague, Inst Rheumatol, Fac Med 1, CZ-12808 Prague, Czech Republic
关键词
INTACT PARATHYROID-HORMONE; SERUM CORTISOL; DIURNAL RHYTHM; GROWTH-HORMONE; IN-VIVO; RESORPTION; OSTEOPROTEGERIN; CALCIUM; ABNORMALITIES; OSTEOCALCIN;
D O I
10.1530/EJE-10-1108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We hypothesized that with the administration of teriparatide (TPTD) treatment at different times, we would be able to modify the physiological circadian rhythm of bone turnover. Methods: The concentration of serum C-terminal telopeptide of collagen type I (beta CTX), serum N-terminal propeptide of procollagen type I (P1NP), serum ionized calcium (iCa), and plasma PTH were measured every 3 h over a 24 h period in 14 postmenopausal osteoporotic women (aged 72.4 +/- 9.3 years) treated with 20 mu g TPTD for long term, given at different times of the day. General linear model-repeated measurements (GLM RM) were performed to analyze the circadian rhythms as well as intergroup comparisons. Results: GLM-RM for both related groups showed a significant influence of time of day on all measured variables except P1NP. The analysis for each group separately provided a powerful model for beta CTX (P < 0.001, eta(2) = 0.496), serum iCa (P < 0.001, eta(2) = 0.423), plasma PTH (P < 0.001, eta(2) = 0.283), and serum PINP (P < 0.001, eta(2) = 0.248). While the evening TPTD treatment showed a marked circadian rhythm for serum beta CTX, the morning TPTD treatment rather suggested circasemidian rhythm. The P1NP rhythm followed a much smaller amplitude of the rhythm than beta CTX. Changes in serum iCa were positively related to changes in serum beta CTX (P < 0.001) and negatively related to changes in PTH (P < 0.001). Conclusion: Timing of TPTD administration may significantly change the 24 h variation in bone turnover markers as well as calcium-parathyroid axis in postmenopausal osteoporotic women.
引用
收藏
页码:643 / 648
页数:6
相关论文
共 50 条
  • [1] PROPHYLACTIC TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - EFFECT ON BONE TURNOVER
    THOMSEN, K
    ACTA ORTHOPAEDICA SCANDINAVICA, 1987, 58 (06): : 708 - 708
  • [2] BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS - EFFECT OF CALCITONIN TREATMENT
    CIVITELLI, R
    GONNELLI, S
    ZACCHEI, F
    BIGAZZI, S
    VATTIMO, A
    AVIOLI, LV
    GENNARI, C
    JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (04): : 1268 - 1274
  • [3] Bone Turnover and the Response to Alendronate Treatment in Postmenopausal Osteoporosis
    S. Gonnelli
    C. Cepollaro
    C. Pondrelli
    S. Martini
    A. Montagnani
    R. Monaco
    C. Gennari
    Calcified Tissue International, 1999, 65 : 359 - 364
  • [4] Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis
    Gonnelli, S
    Cepollaro, C
    Pondrelli, C
    Martini, S
    Montagnani, A
    Monaco, R
    Gennari, C
    CALCIFIED TISSUE INTERNATIONAL, 1999, 65 (05) : 359 - 364
  • [5] BONE MINERAL DENSITY AND BONE TURNOVER MARKERS AFTER ONE-YEAR TERIPARATIDE TREATMENT IN KOREAN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Oh, H.
    Choi, W.
    Choi, H.
    Kim, J.
    Lim, S.
    Joo, I.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 183 - 184
  • [6] Effect of raloxifene after teriparatide treatment in postmenopausal women with osteoporosis
    Adami, S.
    Munoz-Torres, M.
    Econs, M. J.
    Sipos, A.
    Xie, L.
    Dalsky, G. P.
    McClung, M.
    Felsenberg, D.
    Brown, J. P.
    Brandi, M. L.
    San Martin, J.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S137 - S137
  • [7] Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
    Delmas, Pierre D.
    Vrijens, Bernard
    Eastell, Richard
    Roux, Christian
    Pols, Huibert A. P.
    Ringe, Johann D.
    Grauer, Andreas
    Cahall, David
    Watts, Nelson B.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04): : 1296 - 1304
  • [8] Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis
    Recker, Robert R.
    Marin, Fernando
    Ish-Shalom, Sophia
    Moericke, Ruediger
    Hawkins, Federico
    Kapetanos, Georgios
    de la Pena, Maria P.
    Kekow, Joern
    Farrerons, Jordi
    Sanz, Beatriz
    Oertel, Heide
    Stepan, Jan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (08) : 1358 - 1368
  • [9] The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis
    Szulc, Pawel
    CLINICAL BIOCHEMISTRY, 2012, 45 (12) : 907 - 919
  • [10] Effects of discontinuation of teriparatide treatment on cortical bone in postmenopausal women with osteoporosis.
    Bogado, CE
    Mango, A
    Sato, M
    Zanchetta, JR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S54 - S54